Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Guggenheim from $12.00 to $8.00. They now have a "buy" rating on the stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib